• The Mnk inhibitor cercosporamide suppresses human leukemic progenitors and exhibits antileukemic effects in a xenograft mouse model.
Introduction
The need for novel therapies for acute myeloid leukemia (AML) remains urgent and of high clinical importance. Multiple signaling pathways that promote leukemic cell survival and proliferation are constitutively activated in AML cells, providing potential therapeutic targets.
Among them, the mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) pathways play central roles in leukemogenesis (1) (2) (3) . MAPK pathways have been previously shown to be involved in the regulation of gene transcription, cell proliferation, and survival (4) . There has been extensive evidence that these pathways regulate normal and malignant hematopoiesis and transduce signals generated by engagement of growth factor and cytokine receptors (1) .
A family of kinases which are key effectors for MAPK pathways includes the Mnk1 and Mnk2 kinases, which regulate phosphorylation of the eukaryotic initiation factor 4E (eIF4E) in response to a variety of signals (5) (6) (7) (8) (9) (10) (11) (12) (13) . eIF4E is a key component of the mRNA cap-binding complex (14) . The phosphorylation of this protein by Mnk1/2 has important functional consequences for mRNA translation and the regulation of malignant cell proliferation (5, 6) .
Inhibition of eIF4E may be an important approach for the development of novel treatments for patients with various malignancies, as this protein appears to be critical for growth and survival of cancer cells (15, 16) as well as malignant transformation (17, 18) . On the other hand, Mnk activity does not appear to be required for normal development (19) .
In prior studies, we demonstrated that Mnk kinases may act as negative feedback regulators in response to antileukemic agents, including arsenic trioxide (As 2 O 3 ) (11) and chemotherapy (cytarabine) (20) . These studies demonstrated that pharmacological inhibition or siRNA For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From targeting of Mnk kinases suppresses leukemic progenitor growth and enhances the antileukemic properties of other antileukemia agents (11, 20) . However, efforts to therapeutically target Mnk pathways for the treatment of leukemias have been limited by the lack of Mnk inhibitor compounds with potential for clinical development.
Cercosporamide was recently identified during a chemical screen for Mnk1 inhibitors (21) .
It was demonstrated that this known orally bioavailable anti-fungal agent, is a potent and selective Mnk inhibitor (21) . Cercosporamide was found to suppress the growth of melanoma lung metastases and colon carcinoma xenograft tumors (21) , but its potential activity against AML cells and other leukemias is unknown. In the present study we examined the effects of cercosporamide on different AML cell lines and primary leukemic progenitors from AML patients. Our data show that cercosporamide is a potent inhibitor of phosphorylation of eIF4E at Ser209 in AML cells and results in potent inhibitory effects on primitive leukemic progenitors (CFU-L) from AML patients. In addition, we found that combinations of low dose cytarabine with cercosporamide result in enhanced antileukemic responses, raising the potential of combinations of cercosporamide with other agents for the treatment of AML.
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Materials and Methods

Cells and Reagents
The U937, MM6, and K562 human leukemia cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and gentamycin. MV4-11 acute myelogenous leukemia cells were purchased from ATCC (American Type Culture Collection Manassas, VA) and cultured in Iscove's modified Dulbecco's medium w/ L-glutamine, 25mM
HEPES with 10% FBS adjusted to contain 1.5 g/L sodium bicarbonate. Cytarabine was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against the phosphorylated form of eIF4E on Ser209 and eIF4E were obtained from Cell Signaling Technology (Danvers, MA). The antibody against GAPDH was purchased from Millipore Corporation (Billerica, MA). The mTOR inhibitor rapamycin was purchased from Calbiochem/EMD (San Diego, CA).
Cercosporamide was from Eli Lilly and Company (Indianapolis, IN).
Cell Lysis and Immunoblotting For the immunoblotting experiments, cells were treated with cercosporamide or rapamycin for the indicated times and lysed in phosphorylation lysis buffer (22, 23) . Immunoblotting using an enhanced chemiluminescence method was performed as in previous studies (22, 23 (21) . Once tumors reached a group mean of 100 mm 3 , animals were randomized to treatment groups-Ara-C (20 mg/ kg qd dosed IP), cercosporamide (10 mg/kg BID, 20 mg/kg qd dosed orally by gavage), Ara-C + cercosporamide combinations (as above), or the relative vehicle controls (captisol for Cercosporamide, water for Ara-C). Cercosporamide was formulated as described previously (21) . Tumor lysates were taken 2 hours after dosing and western blot analyses were performed as described with antibodies against eIF4E, peIF4E on serine 209 and β -actin, as described (21) .
Cell Proliferation/Viability Assays Such assays using the MTT methodology were conducted as in our previous studies (24, 25) .
Hematopoietic Progenitor Cell Assays. Peripheral blood was obtained from patients with AML after obtaining informed consent in accordance with the Declaration of Helsinki and approval from the Northwestern University Institutional Review Board. Clonogenic assays in methylcellulose were performed as in previous studies (20, 24) .
Results
In initial studies, we examined the effects of cercosporamide on phosphorylation of eIF4E in AML cells. In experiments using the U937 acute myelomonocytic leukemia cell line, we found that cercosporamide potently inhibited phosphorylation of eIF4E on serine 209 (Fig. 1A) .
Similar results were obtained when the effects of cercosporamide were assessed on the AML line MM6 (Fig. 1B) , and the acute erythroleukemia cell line K562 (Fig. 1C) . The inhibitory effects of cercosporamide on eIF4E were dose-dependent with partial suppression of phosphorylation seen at concentration of cercosporamide of 1 μM and maximizing at 5-10 μM (Fig.1D ).
To determine whether cercosporamide exhibits negative regulatory effects on cell proliferation and viability of leukemia cells, MTT assays were conducted. When U937 cells were incubated in the presence or absence of the increasing doses of cercosporamide, we found dose-dependent suppression of cell growth ( In subsequent studies, the effects of Mnk inhibition on primitive leukemic progenitor colony formation were examined. When U937 cells were treated with increasing concentrations of cercosporamide in a methylcellulose culture system, there were dose-dependent suppressive effects on leukemic progenitor colony formation (CFU-L) (Fig. 2D) . Also, when the effects of Mnk inhibition on the antileukemic effects of cytarabine were examined, we found that the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From combination of cercosporamide and cytarabine led to more potent inhibitory effects on CFU-L growth than with either alone (Fig. 2E ).
We next sought to determine whether Mnk inhibition might similarly enhance the effects of cytarabine (Ara-C) in vivo using MV-411 AML xenograft tumors. MV4-11 cells were used to generate the xenograft tumors, as in immunoblotting studies we found that these cells do not express the Jak3 protein (data not shown), whose kinase activity is also inhibited by or Ara-C alone. In each treatment group, mean body weights increased over the course of the study (Fig. 3B) . Further, tumor volume data were evaluated in relation to body weight for each mouse during treatment and revealed no significant effects of body weight on tumor volume
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From (data not shown). Finally, eIF4E serine 209 phosphorylation was reduced in all xenografted tumors treated with cercosporamide (Fig. 3C) .
We have previously shown that treatment of AML cells with rapamycin results in phosphorylation of eIF4E on Ser 209, consistent with Mnk activation via a feedback loop (20) .
To determine whether cercosporamide can modulate the effects of antileukemic effects of rapamycin by blocking this negative feedback loop, its effects on rapamycin-dependent phosphorylation of eIF4E were first examined. As shown in Fig. 4A , treatment with rapamycin enhanced phosphorylation of eIF4E on Ser209 (Fig. 4A) . Such phosphorylation was completely abrogated by concomitant treatment of the cells with cercosporamide (Fig. 4A ). In addition, the combination of rapamycin with cercosporamide resulted in enhanced suppressive effects on CFU-L colony formation, as compared to each agent alone (Fig. 4B) . Thus, cercosporamide enhances the antileukemic effects of mTORC1 inhibition by blocking Mnk/eIF4E phosphorylation.
In subsequent studies we examined the effects of cercosporamide on leukemic precursors from different AML patients. The effects of cercosporamide against leukemic CFU-L were assessed in clonogenic assays in methylcellulose. There was dose-dependent suppression of primary CFU-L colony formation (Fig. 5A) . Importantly, combinations of cercosporamide with rapamycin ( Fig. 5B) or with low doses of cytarabine (Fig. 5C ) resulted in enhanced antileukemic activity when compared to either of these agents alone.
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Discussion
eIF4E is a key eukaryotic initiation translation factor in mammalian cells and its function is critical for mRNA translation of genes whose protein products mediate mitogenic responses, such as c-Myc and cyclin D1 (5, 26) . De-regulation of eIF4E promotes leukemogenesis, making it an attractive target for the treatment of leukemias (27) (28) (29) . This has resulted in efforts to inhibit its function and/or expression for the treatment of AML (29) . One approach to directly target eIF4E in the past has been the use of antisense compounds against eIF4E (30).
LY2275796 is an antisense oligonucleotide against eIF4E that was developed and studied in solid tumors and found to decrease tumor growth in vitro and in vivo (30) , prompting clinical trials in patients with advanced cancers. In a phase I trial, of the 30 patients who received at least one dose of the eIF4E antisense oligonucleotide, 7 patients had stable disease of at least 6 weeks duration and 2 patients had disease control for over 3 months (31) . Other efforts have included the use of the ribavirin, an antiviral drug which may mimic the m 7 G cap to block eIF4E activity (27) . A clinical trial of ribavirin was conducted in patients with AML and among the 11 evaluable patients, there was 1 complete remission (CR) and 2 partial remissions (PRs) (32) .
Notably, response was found to be associated with re-localization of nuclear eIF4E to the cytoplasm and a decrease in the levels of eIF4E expression (32) . does not appear to be a requirement for normal cellular development and growth (19) .
In the current study we examined the effects of cercosporamide, a relatively selective and orally bioavailable Mnk1 inhibitor (21) , which was previously shown to have activity against experimental melanoma lung metastases and subcutaneous colon carcinoma xenograft tumors (21) . Our data demonstrate that cercosporamide inhibits phosphorylation of eIF4E on Ser209 in For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
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